Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China
Launched by ASTRAZENECA · Nov 2, 2016
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
This is a multicentre, nationwide and cross-sectional study carried out in China, covering 30 sites and 3000 patients totally. As for the ratio of tertiary to secondary general hospitals is approximately 1:4 in China, 6 tertiary and 24 secondary hospitals will be randomly selected in this study.To adapt the representativeness of the data with the operational feasibility, 30 tertiary and 120 secondary hospitals will be randomly selected over the 6 geographic regions (north, northeast, east, south central, southwest and northwest). Among those, 1 tertiary and 4 secondary hospitals in each reg...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Provision of subject informed consent
- • 2. Consecutive female and/or male GI outpatients aged 18 years and over
- Exclusion Criteria:
- • 1. Subject with a cognitive condition and unable to finish the questionnaire
- • 2. Subject has an acute or chronic non-GI condition; e.g., doesn't record a 'yes' response to the question, 'Do you have a gut problem?'
Trial Officials
Xiaohua Hou, PhD
Study Chair
Wuhan Union Hospital, China
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials